Canaccord Genuity Assumes Corcept Therapeutics (CORT) at Buy

June 27, 2022 5:18 AM EDT
Get Alerts CORT Hot Sheet
Price: $24.14 -0.74%

Rating Summary:
    9 Buy, 6 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 31 | New: 13
Join SI Premium – FREE

Canaccord Genuity analyst Edward Nash assumes coverage on Corcept Therapeutics (NASDAQ: CORT) with a Buy rating and a price target of $34.00.

For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.

Shares of Corcept Therapeutics closed at $23.80 yesterday.

You May Also Be Interested In

Related Categories

New Coverage